Kung Winston — SEC Form 4 filings
SEC reporting owner CIK 1666963. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-12.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-06-28 to 2026-06-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 2,026 shares, $16,033 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 2,026 shares @ $7.91 ($16,033) in Corbus Pharmaceuticals Holdings, Inc., filed 2026-06-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Director | 4 | — | 1 leg · 2,026 sh · $16,033 | 6 |
| Janux Therapeutics, Inc. (JANX) | Director | 3 | — | — | 6 |
| ArriVent BioPharma, Inc. (AVBP) | Chief Financial Officer | 2 | — | — | 2 |
Form 4 filings — Kung Winston
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-12 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Sale (S): 2,026 @ $7.91 | EDGAR |
| 2026-05-21 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Grant/award (A): 3,800 @ $0 · Grant/award (A): 12,300 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Grant/award (A): 4,800 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Grant/award (A): 5,566 @ $0 · Grant/award (A): 5,566 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 2,500 @ $0 · Grant/award (A): 8,350 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1666963 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →